Celldex Therapeutics (NASDAQ:CLDX) Upgraded to Strong-Buy at Mizuho

Celldex Therapeutics (NASDAQ:CLDX) was upgraded by stock analysts at Mizuho to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other research firms have also issued reports on CLDX. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. HC Wainwright lowered their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, August 20th. Barclays initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 13th. They set an “underweight” rating and a $25.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, September 17th. Finally, Wells Fargo & Company dropped their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.20.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $26.72 on Monday. The firm’s 50 day simple moving average is $24.83 and its 200 day simple moving average is $21.97. Celldex Therapeutics has a one year low of $14.40 and a one year high of $29.38. The company has a market cap of $1.77 billion, a PE ratio of -8.88 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.13 million. Equities research analysts expect that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently made changes to their positions in CLDX. GAMMA Investing LLC grew its stake in shares of Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 2,933 shares in the last quarter. Values First Advisors Inc. boosted its holdings in shares of Celldex Therapeutics by 3.2% in the 1st quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 924 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Celldex Therapeutics in the 1st quarter worth about $269,000. GSA Capital Partners LLP purchased a new position in shares of Celldex Therapeutics in the 1st quarter worth about $1,131,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Celldex Therapeutics by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company’s stock worth $70,757,000 after buying an additional 16,440 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.